Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-10-04
2005-10-04
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S185100, C424S186100, C424S204100, C424S689000, C424S690000, C424S698000, C514S002600, C514S015800, C530S300000, C530S328000
Reexamination Certificate
active
06951651
ABSTRACT:
We have screened the HCMV-specific T cell clone, 33F4, with a nonamer PS-SCL based on SEQ ID NO: 1, and described a series of analog peptides that are recognized with greater affinity than the native peptide sequence.
REFERENCES:
patent: 4689225 (1987-08-01), Pereira
patent: 5248768 (1993-09-01), Lussenhop et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5635363 (1997-06-01), Altman et al.
patent: 6074645 (2000-06-01), Diamond et al.
patent: 6156317 (2000-12-01), Diamond et al.
patent: 6251399 (2001-06-01), Diamond et al.
patent: 6544521 (2003-04-01), Diamond
patent: 6562345 (2003-05-01), Diamond
patent: 6632435 (2003-10-01), Diamond
patent: 6726910 (2004-04-01), Diamond
patent: 6727093 (2004-04-01), Diamond
patent: 6733973 (2004-05-01), Diamond
patent: 6843992 (2005-01-01), Diamond
patent: 2002/0146820 (2002-10-01), Diamond
patent: 2003/0118602 (2003-06-01), Diamond
patent: 2003/0190328 (2003-10-01), Diamond
patent: 2003/0224980 (2003-12-01), Diamond
patent: 2004/0086520 (2004-05-01), Diamond
patent: 2004/0101534 (2004-05-01), Diamond
patent: 2004/0161843 (2004-08-01), Diamond
patent: 2004/0209314 (2004-10-01), Lang et al.
patent: 2004/0265325 (2004-12-01), Diamond et al.
patent: PCT 94/00150 (1994-01-01), None
Zala et al, Hematology, 2000, pp. 339-355.
Diamond et al, Blood, 1997, 90/5:1751-1767.
Prosch et al, biol. Chem. Hoppe-Seyler, 1996, 377:195-201.
Corr et al, Methods in Microbiology, 2002, 32:527-550.
Lore et al, J. Immunology, 2003, 171:4320-4328.
Temperton et al, J. Medical Virology, 2003, 70:86-90.
Endresz et al, Vaccine, 2001, 19:3972-3980.
Benmohamed et al, Immunology, 2002, 106:113-121.
Andersson et al, Current Opinion in Immunology, 2002, 14:409-412.
Alexander et al., “Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides,” Immunity 1:751-761, Dec. 1994.
Borysiewicz et al., “Human Cytomegalovirus-Specific Cytotoxic T Cells,” J. Exp. Med 168:919-931, Sep. 1988.
Brouwenstijn et al., “Definition if Unique and Shared T-Cell Defined Tumor Antigens in Human Renal Cell Carcinoma,” Journal of Immunotherapy 21(6):427-434, 1998.
Carruth et al., “An Algorithm for Evaluating Human Cytotoxic t Lymphocyte Responses to Candidate AIDS Vaccines,” Aids Research and Human Retroviruses 15(11):1021-1034, 1999.
Chujoh et al., “The role of anchor residues in the binding of peptides to HLA-A*1101 molecules,” Tissue Antigens 52:501-509, 1998.
D'Amaro et al., “A Computer Program for Predicting Possible Cytotoxic T Lymphoctye Epitopes Based on HLA Class I Peptide-Binding Motifs,” Human Immunology 43:13-18, 1995.
Del Val et al., “Efficient Processing of an Antigenic Sequence for Presentation by MHC Class I Molecules Depends on its Neighboring Residues in the Protein,” Cell 66:1145-1153, Sep. 20, 1991.
Del Val et al., “Protection Against Lethal Cytomegalovirus Infection by a Recombinant Vaccine Containing a Single Nonameric T-Cell Epitope,” Journal of Virology 65(7):3641-3646, Jul. 1991.
Diamond et al., “Development of a Candidate HLA A*0201 Restricted Peptide-Based Vacicne Against Human Cytomegalovirus Infection,” Blood 90(5):1751-1767, Sep. 1, 1997.
Drijfhout et al., “Detailed Motifs for peptide Binding to HLA-A*0201 Derived from Large Random Sets of Peptides Using a Cellular Binding Assay,” Human Immunology 43:1-12, 1995.
Ellis et al., Chapter 29, “New Technologies for Making Vaccines”, pp. 568-575.
Falk et al., “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules,” Nature 351:290-296, May 23, 1991.
Fremont et al., “Crystal Structures of Two Viral Peptides in Complex with Murine MHC Class I H-2Kb,” Science 257:919-927, Aug. 14, 1992.
Gönczöl et al., “Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate,” Vaccine 13(12):1080-1085, 1995.
Greenberg et al., “Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Recipients by Adoptive Transfer of Donor-Derived CMV-Specific T Cell Clones Expanded in Vitro,” Annals of the New York Academy of Sciences (Antigen and Clone-Specific Immunoregulation) 636:184-195, 1991.
Gundlach et al., “Specificity and Degeneracy of Minor Histocompatibility Antigen-Specific MHC-Restricted CTL,” J. Immunol. 156:3645-3651, 1996.
Hemmer et al., “Cutting Edge: Predictable TCR Antigen Recognition Based on Peptide Scans Leads to the Identification of Agonist Ligands with No Sequence Homology,” J. Immunology 160:3631-3636, 1998.
Kawashima et al., “The Multi-epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors,” Human Immunology 59:1-14, 1998.
Khattab et al., “Three T-Cell Epitopes Within the C-Terminal 265 Amino Acids of the Matrix Protein pp65 of Human Cytomegalovirus Recognized by Human Lymphocytes,” J. Med. Virol. 52:68-76, 1997.
Larosa et al., “Development of In Vitro Stimulation (IVS) Protocol to Measure CMV Specific CTL Activity Using HLA-Restricted Specific CtL Epitopes,”,Blood 92(10 -suppl. 1):518a, 1998 (Abstract 2129).
Leggatt et al., “The Importance of Pairwise Interactions Between Peptide Residues in the Delineation of TCR Specificity,” J. Immunology 161:4728-4735, 1998.
Lipford et al., “Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6,” Immunology 84:298-303, 1995.
Madden et al., “The Antigenic Identity of Peptide-MHC Complexes: A Comparison of the Conformations of Five Viral Peptides Presented by HLA-A2,” Cell 75:693-708, Nov. 19, 1993.
McLaughlin-Taylor et al., “Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8+Virus-Specific Cytotoxic T Lymphocytes,” J. Med. Virol. 43:103-110, 1994.
Nijman et al., “Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes,” Eur. J. Immunol. 23:1215-1219, 1993.
Ono et al., “Alterations in TCR-MHC Contacts Subsequent to Cross-Recognition of Class I MHC and Singly Substituted Peptide Variants,” J. Immunol. 161:5454-5463 (1998).
Oseroff et al., “Pools of lipidated HTL-CTL construct prime for multiple HBV and HCV CTL eptiope responses,” Vaccine 16(8):823-833, 1998.
Pande et al., “Human Cytomegalovirus Strain Towne pp65 gene: Nucleotide Sequence and Expression inEscherichia coli,” Virology 182:220-228, 1991.
Parkhurst et al., “Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Resiudes,” J. Immunol. 157:2539-2548, 1996.
Rammensee et al., “MHC ligands and peptide motifs: first listing,” Immunogenetics 41:178-228, 1995.
Rammensee et al., “Peptide Naturally Presented by MHC Class I Molecules,” Annu. Rev. Immunol. 11:213-44, 1993.
Rasmussen, “Immune Response to Human Cytomegalovirus Infection,” Current Topics in Microbiology and Immunology 154:222-254, 1990.
Schulz et al., “Peptide-induced antiviral protection by cytotoxic T cells,” Proc. Natl. Acad. Sci. USA 88:991-993, Feb. 1991.
Sette et al., “Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays,” Molecular Immunol. 31(11):813-822, 1994.
Sette et al., “The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes,” J. Immunol. 153:5586-5592, 1994.
Valmori et al., “Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/Mart-1 Antigenic Peptide,” J. Immunol. 161:6956-6962, 1998.
V
City of Hope
Minnifield N. M.
Rothwell Figg Ernst & Manbeck p.c.
LandOfFree
CTL epitope analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CTL epitope analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CTL epitope analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467864